Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Better fracture treatment for osteoporotic patinets

Reference number
Coordinator Inossia AB
Funding from Vinnova SEK 500 000
Project duration December 2015 - December 2016
Status Completed

Purpose and goal

The aim of the project was to bring Inossia´s bone cement closer to a market introduction. Inossia´s bone cement is modified with an additive so that it can match the stiffness of osteoporotic bone and improve the prospects for many osteoporotic patients to continue living an active life after a vertebral fracture. All goals were fulfilled; signed a contract with an international cement manufacturing partner with own sales channels, developed a business plan and a plan for the regulatory application for CE mark and started the patent processes in the EU, USA, China, Korea and India.

Expected results and effects

The anticipated end result was fulfilled and Inossia now have a signed contract with an international partner and an elaborated business plan in place where Inossia will care for the manufacture of the additive and the partner will care for the bone cement manufacturing. These are important decisions since it improves the route for a faster development of the regulatory application for CE mark. Once the CE approval is achieved, the market introduction will be performed by the partner´s network of surgeons. Patent protection processes have started in the EU, USA, China, Korea and India.

Planned approach and implementation

The activities were divided into five work packages with the following results: WP1: We summarized the results from an ongoing animal study in sheep at NAMSA in a scientific article to be published during 2017. This article will be used in contact with potential customers and regulatory authorities. WP2: We developed a business plan WP3: We signed a contract with an international cement manufacturer WP4: Clarified the optimal regulatory pathway for CE mark WP5: Started patent processes in identified key regions (Europe, USA, China, Korea and India)

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 25 November 2019

Reference number 2015-05587

Page statistics